Viet Nguyen
Nurse Practitioner · Tacoma, WANPI 1386709384
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,060 of the $9,644 with a category attached, or 73.2%. 34 manufacturers reported payments, led by Medtronic at 35.4% of the total. Reporting peaked in 2022 at $5,694 and has fallen 86.2% since, to $785 in 2025. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $25.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Mannkind Corporation$738
- Novo Nordisk$677
- Sanofi-aventis U.S. LLC$596
- Lilly USA, LLC$464
- Abbott$433
- plus $3K from 28 others
What the payments were for
- Travel & lodging$2,37525%
- Food & beverage$7,06073%
- Education$1502%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 57 | $3,418 |
| Mannkind Corporation | 63 | $738 |
| Novo Nordisk | 61 | $677 |
| Sanofi-aventis U.S. LLC | 22 | $596 |
| Lilly USA, LLC | 31 | $464 |
| Abbott | 16 | $433 |
| Boehringer Ingelheim | 22 | $393 |
| Boston Scientific | 4 | $372 |
| Amgen | 15 | $331 |
| AbbVie | 13 | $275 |
| Corcept Therapeutics | 12 | $264 |
| BETA Bionics, Inc. | 2 | $219 |
| Tandem Diabetes Care, Inc. | 2 | $202 |
| Xeris Pharmaceuticals, Inc. | 9 | $160 |
| Amryt Pharma Holdings Ltd | 5 | $137 |
| Bayer | 5 | $125 |
| Antares Pharma, Inc. | 7 | $117 |
| Insulet Corporation | 5 | $109 |
| Dexcom, Inc. | 5 | $103 |
| Novartis | 5 | $98 |
| AstraZeneca | 4 | $65 |
| Zealand Pharma US, Inc. | 3 | $64 |
| Recordati_rare_diseases_inc. | 3 | $59 |
| Sequel Med Tech, LLC | 2 | $44 |
| IBSA Pharma Inc. | 2 | $40 |
| EUSA Pharma (US) LLC | 1 | $23 |
| Lifescan, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $17 |
| Inspiremd Ltd | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Pfizer | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $13 |
| Medicure Pharma Inc. | 1 | $12 |
| Cequr Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$2,113
- iLet Bionic Pancreas$658
- RYBELSUS$227
- FREESTYLE LIBRE 3$152
- EXALT Model D$134
- t:slim X2 Insulin Pump with Control-IQ$133
- TZIELD$115
- ACQUIRE$111
- Rinvoq$109
- AXIOS$104
How this compares
$9,644 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $202,852 |
| JardianceEmpagliflozin | 115 | $131,912 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 85 | $101,096 |
| TrulicityDulaglutide | 45 | $81,171 |
| Humalog Kwikpen U-200Insulin Lispro | 32 | $73,748 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $63,152 |
| MounjaroTirzepatide | 17 | $27,362 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $26,162 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $24,965 |
| Humalog Kwikpen U-100Insulin Lispro | 86 | $23,552 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 145 | $22,624 |
| NovologInsulin Aspart | 53 | $21,742 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $21,465 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 46 | $13,928 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $13,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $677 | $224,594166 claims |
| Boehringer IngelheimJardiance | $393 | $131,912115 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $464 | $115,84587 claims |
| AstraZenecaFarxiga | $65 | $7,98412 claims |
| Sanofi-aventis U.S. LLCLantus | $596 | $1,72922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Tacoma
- Megan WildesTacoma$72K
- Sharon JungTacoma$23K
- Loan RetchlessTacoma$21K
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Felicia ForrestLynnwood$206K
- Amaris MurphyBellevue$146K
- Sonia GlennieSeattle$78K
- Kate KennedyBellevue$63K
- Vicki HainesPasco$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.